The endocannabinoid system and appetite: Relevance for food reward

Nutrition Research Reviews

Volumn 27, Issue 1, 2014, Pages 172-185

  Jager, Gerry ^a   Witkamp, Renger F ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Appetite; Eating behaviour; Endocannabinoid system; Food reward value

Indexed keywords

CANNABINOID; CANNABIS; ENDOCANNABINOID; RIMONABANT;

ANOREXIA; APPETITE; DIETARY INTAKE; EATING DISORDER; ENERGY BALANCE; FEEDING; FOOD INTAKE; FOOD REWARD; FRAIL ELDERLY; HOMEOSTASIS; HUMAN; MALNUTRITION; MOTIVATION; NEUROPHYSIOLOGY; NONHUMAN; OBESITY; ORIENTATION; PALATABILITY; PSYCHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 84903895185     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422414000080     Document Type: Review

References (161)

1. Kirkham TC. (2009). Endocannabinoids and the nonhomeostatic control of appetite. Curr Top Behav Neurosci 1, 231-253
2. Kirkham TC & Tucci SA. (2006). Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 5, 275-292
3. Bellocchio L, Cervino C, Pasquali R, et al. (2008). The endocannabinoid system and energy metabolism. J Neuroendocrinol 20, 850-857
4. Pagotto U, Cervino C, Vicennati V, et al. (2006). How many sites of action for endocannabinoids to control energy metabolism?. Int J Obes 30, Suppl. 1, S39-S43
5. Matias I, Bisogno T & Di Marzo V. (2006). Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes 30, Suppl. 1, S7-S12
6. Cota D, Marsicano G, Tschöp M, et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112, 423-431
7. Abel EL. (1971). Effects of marihuana on the solution of anagrams, memory and appetite. Nature 231, 260-261
8. Kirkham TC & Williams CM. (2001). Endogenous cannabinoids and appetite. Nutr Res Rev 14, 65-86
9. Silvestri C & Di Marzo V. (2013). The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 17, 475-490
10. Pertwee RG. (2012). Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc B Biol Sci 367, 3353-3363
11. Marco EM, Romero-Zerbo SY, Viveros MP, et al. (2012). The role of the endocannabinoid system in eating disorders: pharmacological implications. Behav Pharmacol 23, 526-536
12. Monteleone P. (2011). New frontiers in endocrinology of eating disorders. Curr Top Behav Neurosci 6, 189-208
13. Rosenson RS. (2009). Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology 114, 212-225
14. Cota D. (2008). The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neurendocrinol 20, Suppl. 1, 35-38
15. Woods SC. (2007). Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med 120, Suppl. 1, S19-S25
16. Woods SC. (2007). The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med 120, Suppl. 1, S9-S17
17. Christensen R, Kristensen PK, Bartels EM, et al. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706-1713
18. Heal DJ, Gosden J & Smith SL. (2009). Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68, 861-874
19. Wernette CM, White BD & Zizza CA. (2011). Signaling proteins that influence energy intake may affect unintentional weight loss in elderly persons. J Am Diet Assoc 111, 864-873
20. Wilner LS & Arnold RM. (2011). Cannabinoids in the treatment of symptoms in cancer and AIDS, 2nd edition #93. J Palliative Med 14, 509-510
21. Glare P, Miller J, Nikolova T, et al. (2011). Treating nausea and vomiting in palliative care: a review. Clin Interventions Aging 6, 243-259
22. Wargent ET, Zaibi MS, Silvestri C, et al. (2013). The cannabinoid D9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes 3, e68
23. Silvestri C & Di Marzo V. (2012). Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Invest Drugs 21, 1309-1322
24. Witkamp RF. (2011). Current and future drug targets in weight management. Pharm Res 28, 1792-1818
25. Bermudez-Silva FJ, Viveros MP, McPartland JM, et al. (2010). The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?. Pharmacol Biochem Behav 95, 375-382
26. Quarta C, Mazza R, Obici S, et al. (2011). Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 17, 518-526
27. Pertwee RG. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17, 1360-1381
28. Matsuda LA, Lolait SJ, Brownstein MJ, et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
29. Munro S, Thomas KL & Abu-Shaar M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65
30. Gertsch J, Pertwee RG & Di Marzo V. (2010). Phytocannabinoids beyond the Cannabis plant -do they exist?. Br J Pharmacol 160, 523-529
31. MacCarrone M, Gasperi V, Catani MV, et al. (2010). The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 30, 423-440
32. Di Marzo V, Bisogno T & De Petrocellis L. (2007). Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 14, 741-756
33. Di Marzo V & De Petrocellis L. (2012). Why do cannabinoid receptors have more than one endogenous ligand?. Philos Trans R Soc B Biol Sci 367, 3216-3228
34. Pertwee RG, Howlett AC, Abood ME, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62, 588-631
35. van Bakel H, Stout JM, Cote AG, et al. (2011). The draft genome and transcriptome of Cannabis sativa. Genome Biol 12, R102
36. Mehmedic Z, Chandra S, Slade D, et al. (2010). Potency trends of D9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55, 1209-1217
37. Skaper SD & Di Marzo V. (2012). Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos Trans R Soc B Biol Sci 367, 3193-3200
38. Robson P. (2005). Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 168, 719-756
39. Verhoeckx KCM, Korthout HAAJ, Van Meeteren-Kreikamp AP, et al. (2006). Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6, 656-665
40. Eichler M, Spinedi L, Unfer-Grauwiler S, et al. (2012). Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Medica 78, 686-691
41. Alexander SPH & Kendall DA. (2007). The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152, 602-623
42. Brown I, Cascio MG, Rotondo D, et al. (2013). Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog Lipid Res 52, 80-109
43. Leishman E, Kokesh KJ & Bradshaw HB. (2013). Lipids and addiction: how sex steroids, prostaglandins, and cannabinoids interact with drugs of abuse. Ann N Y Acad Sci 1282, 25-38
44. Overton HA, Fyfe MCT & Reynet C. (2008). GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153, Suppl. 1, S76-S81
45. Sylantyev S, Jensen TP, Ross RA, et al. (2013). Cannabinoidand lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci USA 110, 5193-5198
46. Tsuboi K, Ikematsu N, Uyama T, et al. (2013). Biosynthetic pathways of bioactive N-acylethanolamines in brain. CNS Neurol Disord Drug Targets 12, 7-16
47. Wellner N, Diep TA, Janfelt C, et al. (2013). N-acylation of phosphatidylethanolamine and its biological functions in mammals. Biochim Biophys Acta 1831, 652-662
48. Reisenberg M, Singh PK, Williams G, et al. (2012). The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc B Biol Sci 367, 3264-3275
49. Bisogno T. (2008). Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 20, Suppl. 1, 1-9
50. Ueda N, Tsuboi K & Uyama T. (2010). Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801, 1274-1285
51. Blankman JL, Simon GM & Cravatt BF. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14, 1347-1356
52. Fonseca BM, Costa MA, Almada M, et al. (2013). Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat 102-103, 13-30
53. Rouzer CA & Marnett LJ. (2011). Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111, 5899-5921
54. Vandevoorde S & Lambert DM. (2007). The multiple pathways of endocannabinoid metabolism: a zoom out. Chem Biodivers 4, 1858-1881
55. Yang R, Fredman G, Krishnamoorthy S, et al. (2011). Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem 286, 31532-31541
56. DiPatrizio NV & Piomelli D. (2012). The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci 35, 403-411
57. Cachope R. (2012). Functional diversity on synaptic plasticity mediated by endocannabinoids. Philos Trans R Soc B Biol Sci 367, 3242-3253
58. Cota D, Tschop MH, Horvath TL, et al. (2006). Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res Rev 51, 85-107
59. Herkenham M, Lynn AB, Little MD, et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87, 1932-1936
60. Freund TF, Katona I & Piomelli D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83, 1017-1066
61. Katona I & Freund TF. (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14, 923-930
62. Fattore L, Melis M, Fadda P, et al. (2010). The endocannabinoid system and nondrug rewarding behaviours. Exp Neurol 224, 23-36
63. Melis M & Pistis M. (2012). Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc B Biol Sci 367, 3276-3285
64. Solinas M, Goldberg SR & Piomelli D. (2008). The endocannabinoid system in brain reward processes. Br J Pharmacol 154, 369-383
65. Matias I, Gatta-Cherifi B & Cota D. (2012). Obesity and the endocannabinoid system: circulating endocannabinoids and obesity. Curr Obes Rep 1, 229-235
66. Hanlon EC, Stuhr K, Leproult R, et al. (2013). Circadian rhythm of circulating endocannabinoid, 2-arachidonoylglycerol concentrations following normal and restricted sleep. 23rd Annual Symposium on the Cannabinoids (ICRS), p. 8. http://www.icrs.co/SYMPOSIUM.2013/ICRS2013. PROGRAMME.pdf (accessed May 2014)
67. Matias I, Gatta-Cherifi B, Tabarin A, et al. (2012). Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLOS ONE 7, e42399
68. Matias I, Gonthier MP, Orlando P, et al. (2006). Regulation, function, and dysregulation of endocannabinoids in models of adipose and b-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91, 3171-3180
69. Monteleone P, Piscitelli F, Scognamiglio P, et al. (2012). Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab 97, E917-E924
70. Joosten MM, Balvers MGJ, Verhoeckx KCM, et al. (2010). Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab 7, 49
71. Kirkham TC, Williams CM, Fezza F, et al. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136, 550-557
72. Hanus? L, Avraham Y, Ben-Shushan D, et al. (2003). Shortterm fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 983, 144-151
73. Massa F, Mancini G, Schmidt H, et al. (2010). Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci 30, 6273-6281
74. Balvers MGJ, Verhoeckx KCM, Bijlsma S, et al. (2012). Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics 8, 1130-1147
75. Hansen HS. (2013). Effect of diet on tissue levels of palmitoylethanolamide. CNS Neurol Disord Drug Targets 12, 17-25
76. Meijerink J, Balvers M & Witkamp R. (2013). N-acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids -from fishy endocannabinoids to potential leads. Br J Pharmacol 169, 772-783
77. Rojo ML, Söderström I, Olsson T, et al. (2013). Changes in cannabinoid CB1 receptor functionality in the female rat prefrontal cortex following a high fat diet. Life Sci 92, 757-762
78. Sanabria-Bohórquez SM, Hamill TG, Goffin K, et al. (2010). Kinetic analysis of the cannabinoid-1 receptor PET tracer [18F]MK-9470 in human brain. Eur J Nuc Med Mol Imaging 37, 920-933
79. Ceccarini J, De Hert M, Van Winkel R, et al. (2013). Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage 79, 304-312
80. Gérard N, Pieters G, Goffin K, et al. (2011). Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry 70, 777-784
81. Coulon D, Faure L, Salmon M, et al. (2012). N-acylethanolamines and related compounds: aspects of metabolism and functions. Plant Sci 184, 129-140
82. Gertsch J. (2008). Immunomodulatory lipids in plants: plant fatty acid amides and the human endocannabinoid system. Planta Medica 74, 638-650
83. Kim S-C, Chapman KD & Blancaflor EB. (2010). Fatty acid amide lipid mediators in plants. Plant Sci 178, 411-419
84. Chapman KD, Venables BJ, Dian EE, et al. (2003). Identification and quantification of neuroactive N-acylethanolamines in cottonseed processing fractions. JAOCS 80, 223-229
85. di Tomaso E, Beltramo M & Piomelli D. (1996). Brain cannabinoids in chocolate. Nature 382, 677-678
86. Leonti M, Casu L, Raduner S, et al. (2010). Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. Biochem Pharmacol 79, 1815-1826
87. Ligresti A, Villano R, Allarà M, et al. (2012). Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB1 receptor ligand. Pharmacol Res 66, 163-169
88. Pertwee RG. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin. Br J Pharmacol 153, 199-215
89. Fride E. (2008). Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and oostnatal development. J Neuroendocrinol 20, Suppl. 1, 75-81
90. Kringelbach ML, Stein A & van Hartevelt TJ. (2012). The functional human neuroanatomy of food pleasure cycles. Physiol Behav 106, 307-316
91. Berridge KC, Ho CY, Richard JM, et al. (2010). The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res 1350, 43-64
92. Berridge KC & Kringelbach ML. (2008). Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology 199, 457-480
93. Berridge KC & Robinson TE. (2003). Parsing reward. Trends Neurosci 26, 507-513
94. Finlayson G, King N & Blundell JE. (2007). Is it possible to dissociate 'liking' and 'wanting' for foods in humans?. A novel experimental procedure. Physiol Behav 90, 36-42
95. Dagher A. (2012). Functional brain imaging of appetite. Trends Endocrinol Metab 23, 250-260
96. Finlayson G, King N & Blundell JE. (2007). Liking vs. wanting food: importance for human appetite control and weight regulation. Neurosci Biobehav Rev 31, 987-1002
97. Havermans RC. (2012). How to tell where 'liking' ends and 'wanting' begins. Appetite 58, 252-255
98. Winkielman P, Berridge KC & Wilbarger JL. (2005). Unconscious affective reactions to masked happy versus angry faces influence consumption behavior and judgments of value. Pers Soc Psychol Bull 31, 121-135
99. Cooper SJ. (2004). Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol 500, 37-49
100. Rogers PJ. (1990). Why a palatability construct is needed. Appetite 14, 167-170
101. Lawless H. (1985). Sensory development in children: research in taste and olfaction. J Am Diet Assoc 85, 577-582
102. Bolhuis DP, Lakemond CM, de Wijk RA, et al. (2010). Effect of salt intensity on ad libitum intake of tomato soup similar in palatability and on salt preference after consumption. Chem Senses 35, 789-799
103. Kirkham TC & Williams CM. (2004). Endocannabinoid receptor antagonists: potential for obesity treatment. Treat Endocrinol 3, 345-360
104. Ravinet Trillou C, Delgorge C, Menet C, et al. (2004). CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes 28, 640-668
105. Sanchis-Segura C, Cline BH, Marsicano G, et al. (2004). Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 176, 223-232
106. Berridge KC. (2009). 'Liking' and 'wanting' food rewards: brain substrates and roles in eating disorders. Physiol Behav 97, 537-550
107. Farrimond JA, Mercier MS, Whalley BJ, et al. (2011). Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Phytother Res 25, 170-188
108. Guegan T, Cutando L, Ayuso E, et al. (2013). Operant behavior to obtain palatable food modifies neuronal plasticity in the brain reward circuit. Eur Neuropsychopharmacol 23, 146-159
109. Barbano MF, Castañé A, Martín-García E, et al. (2009). Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test. Psychopharmacology 205, 475-487
110. Freedland CS, Poston JS & Porrino LJ. (2000). Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 67, 265-270
111. Gallate JE, Saharov T, Mallet PE, et al. (1999). Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 370, 233-240
112. Thornton-Jones ZD, Vickers SP & Clifton PG. (2005). The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology 179, 452-460
113. Maccioni P, Pes D, Carai MAM, et al. (2008). Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolateflavoured beverage in rats. Behav Pharmacol 19, 197-209
114. Salamone JD, McLaughlin PJ, Sink K, et al. (2007). Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91, 383-388
115. Thornton-Jones ZD, Kennett GA, Vickers SP, et al. (2007). A comparison of the effects of the CB1 receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour. Psychopharmacology 193, 1-9
116. DiPatrizio NV & Simansky KJ. (2008). Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 28, 9702-9709
117. Shinohara Y, Inui T, Yamamoto T, et al. (2009). Cannabinoid in the nucleus accumbens enhances the intake of palatable solution. NeuroReport 20, 1382-1385
118. Koch JE & Matthews SM. (2001). D9-Tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration. Nutr Neurosci 4, 179-187
119. Williams CM & Kirkham TC. (1999). Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143, 315-317
120. Williams CM, Rogers PJ & Kirkham TC. (1998). Hyperphagia in pre-fed rats following oral d9-THC. Physiol Behav 65, 343-346
121. Higgs S, Williams CM & Kirkham TC. (2003). Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after D9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 165, 370-377
122. Grill HJ & Norgren R. (1978). The taste reactivity test. II. Mimetic responses to gustatory stimuli in chronic thalamic and chronic decerebrate rats. Brain Res 143, 281-297
123. Berridge KC. (2000). Reward learning: reinforcement, incentives, and expectations. Psychol Learn Motiv 40, 223-278
124. Jarrett MM, Limebeer CL & Parker LA. (2005). Effect of D9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiol Behav 86, 475-479
125. Jarrett MM, Scantlebury J & Parker LA. (2007). Effect of D9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav 90, 425-430
126. Mahler SV, Smith KS & Berridge KC. (2007). Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32, 2267-2278
127. Berthoud HR. (2007). Interactions between the cognitive and metabolic brain in the control of food intake. Physiol Behav 91, 486-498
128. Fulton S. (2010). Appetite and reward. Front Neuroendocrinol 31, 85-103
129. Jyotaki M, Shigemura N & Ninomiya Y. (2010). Modulation of sweet taste sensitivity by orexigenic and anorexigenic factors. Endocr J 57, 467-475
130. Yoshida R, Ohkuri T, Jyotaki M, et al. (2010). Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 107, 935-939
131. Tart CT. (1970). Marijuana intoxication: common experiences. Nature 226, 701-704
132. Haines L & Green W. (1970). Marijuana use patterns. Br J Addict Alcohol Other Drugs 65, 347-362
133. Mattes RD, Engelman K, Shaw LM, et al. (1994). Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49, 187-195
134. Foltin RW, Brady JV & Fischman MW. (1986). Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25, 577-582
135. Foltin RW, Fischman MW & Byrne MF. (1988). Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11, 1-14
136. Mattes RD, Shaw LM & Engelman K. (1994). Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 19, 125-140
137. Le Foll B, Trigo JM, Sharkey KA, et al. (2013). Cannabis and D9-tetrahydrocannabinol (THC) for weight loss?. Med Hypotheses 80, 564-567
138. Matias I & Di Marzo V. (2007). Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18, 27-37
139. Cervino C, Vicennati V, Pasquali R, et al. (2009). Feeding disorders and obesity. Curr Top Behav Neurosci 1, 373-385
140. Monteleone P, Bifulco M, Di Filippo C, et al. (2009). Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. Genes Brain Behav 8, 728-732
141. Monteleone P, Castaldo E & Maj M. (2008). Neuroendocrine dysregulation of food intake in eating disorders. Regul Pept 149, 39-50
142. Schroeder M, Eberlein C, de Zwaan M, et al. (2012). Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: association with wrist cutting as impulsive self-injurious behavior. Psychoneuroendocrinology 37, 2032-2036
143. Serra-Prat M, Mans E, Palomera E, et al. (2013). Gastrointestinal peptides, gastrointestinal motility, and anorexia of aging in frail elderly persons. Neurogastroenterol Motil 25, 291-e245
144. Volicer L, Stelly M, Morris J, et al. (1997). Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriat Psychiatry 12, 913-919
145. Brisbois TD, de Kock IH, Watanabe SM, et al. (2011). Delta- 9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22, 2086-2093
146. Pertwee RG. (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156, 397-411
147. Beal JE, Olson R, Laubenstein L, et al. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10, 89-97
148. Dejesus E, Rodwick BM, Bowers D, et al. (2007). Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc Physicians AIDS Care (Chic) 6, 95-100
149. Gamper EM, Zabernigg A, Wintner LM, et al. (2012). Coming to your senses: detecting taste and smell alterations in chemotherapy patients. a systematic review. J Pain Symptom Manage 44, 880-895
150. Schiffman SS. (2007). Critical illness and changes in sensory perception. Proc Nutr Soc 66, 331-345
151. Kim SF. (2012). Animal models of eating disorders. Neuroscience 211, 2-12
152. Keller A & Vosshall LB. (2008). Better smelling through genetics: mammalian odor perception. Curr Opin Neurobiol 18, 364-369
153. Yeomans MR. (2000). Rating changes over the course of meals: what do they tell us about motivation to eat?. Neurosci Biobehav Rev 24, 249-259
154. Yeomans MR, Blundell JE & Leshem M. (2004). Palatability: response to nutritional need or need-free stimulation of appetite?. Br J Nutr 92, Suppl. 1, S3-S14
155. Jenkins BG. (2012). Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. NeuroImage 62, 1072-1085
156. Ameloot K, Janssen P, Scarpellini E, et al. (2010). Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther 31, 1123-1131
157. Storr MA & Sharkey KA. (2007). The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 7, 575-582
158. Dickson SL, Egecioglu E, Landgren S, et al. (2011). The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol 340, 80-87
159. Perelló M & Zigman JM. (2012). The role of ghrelin in reward-based eating. Biol Psychiatry 72, 347-353
160. Smeets PAM, Erkner A & De Graaf C. (2010). Cephalic phase responses and appetite. Nutr Rev 68, 643-655
161. Joosten MM, de Graaf C, Rietman A, et al. (2010). Short-term oral exposure to white wine transiently lowers serum free fatty acids. Appetite 55, 124-129